Tuesday, Aug. 7 promises to be great day of lectures. All of Tuesday’s General Sessions will be held in Moscone Center West, Room 3006-3012.
At the Tuesday morning General Session, New York Times regular contributorTheresa Brown, RN, BSN, OCN, will present ‘Bullying in the OR: A Threat to Patient Safety." Brown will focus on the prevalence of bullying in the OR, behaviors that can be considered bullying, and strategies to address the bully effectively. The session will take place from 7 to 8 a.m.
From 10 to 11 a.m. in Room 3006-3012, Suzanne Wright, CRNA, PhD, will present “Primum Non Nocere—First Do No Harm." Wright, the director of the Center for Research in Human Simulation, Virginia Commonwealth University, will examine some of the not-so-uncommon practices within anesthesia that actually place patients in harm’s way—perhaps contributing to patient injury.
From 11 a.m. to 12 p.m., Author of “Younger Next Year,” Chris Crowley will present the 2012 Jan Stewart Memorial Wellness Lecture. Learn how life changes can lessen the negative impact of aging. Crowley will present tips on changes you can make to improve your life.
From 1:30 to 2:30 p.m., Linda Callahan CRNA, PhD, will present “Patient Outcomes: Does Continuing Education Make a Difference?”Callahan will evaluate continuing professional education in general and provide specific insight into its applicability to the nurse anesthesia community in terms of perceived and actual effectiveness. An AANA Past President, Callahan is professor emeritus, School of Nursing, California State University, Long Beach, Calif.
From 2:30 to 4:30 p.m., “Perioperative Neuromuscular Blockade: Time for Another Look” will feature two experienced anesthesia providers, Mark Welliver, CRNA, DNP, ARNP, and Glenn Murphy, MD, sharing their views and knowledge on neuromuscular blocking agents and pertinent information for perioperative patient care associated with this category of pharmaceuticals. This General Session was made possible with funding provided through an independent, unrestricted grant from Merck & Co., Inc.